Rothschild Capital Partners LLC lowered its stake in St. Jude Medical Inc. (NYSE:STJ) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 83,329 shares of the medical technology company’s stock after selling 2,301 shares during the period. St. Jude Medical makes up approximately 3.4% of Rothschild Capital Partners LLC’s investment portfolio, making the stock its 12th largest position. Rothschild Capital Partners LLC’s holdings in St. Jude Medical were worth $6,500,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Norges Bank bought a new stake in St. Jude Medical during the fourth quarter valued at about $135,144,000. Renaissance Technologies LLC increased its stake in shares of St. Jude Medical by 138.2% in the first quarter. Renaissance Technologies LLC now owns 1,920,213 shares of the medical technology company’s stock worth $105,612,000 after buying an additional 1,114,100 shares during the period. Bridger Management LLC acquired a new stake in shares of St. Jude Medical during the first quarter worth about $50,105,000. BNP Paribas Arbitrage SA increased its stake in shares of St. Jude Medical by 515.9% in the second quarter. BNP Paribas Arbitrage SA now owns 557,962 shares of the medical technology company’s stock worth $43,521,000 after buying an additional 467,365 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of St. Jude Medical by 31.2% in the first quarter. Bessemer Group Inc. now owns 1,749,283 shares of the medical technology company’s stock worth $96,211,000 after buying an additional 415,641 shares during the period. Hedge funds and other institutional investors own 81.77% of the company’s stock.

Shares of St. Jude Medical Inc. (NYSE:STJ) traded down 0.19% during mid-day trading on Tuesday, reaching $78.89. 1,942,552 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $80.85 and a 200 day moving average price of $73.07. The firm has a market capitalization of $22.48 billion, a price-to-earnings ratio of 34.30 and a beta of 1.32. St. Jude Medical Inc. has a 12-month low of $48.83 and a 12-month high of $84.00.

St. Jude Medical (NYSE:STJ) last announced its earnings results on Wednesday, July 20th. The medical technology company reported $1.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.06. The firm had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.55 billion. St. Jude Medical had a net margin of 11.40% and a return on equity of 27.60%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 EPS. Analysts anticipate that St. Jude Medical Inc. will post $4.06 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be given a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a dividend yield of 1.57%. The ex-dividend date is Wednesday, September 28th. St. Jude Medical’s dividend payout ratio is 53.91%.

A number of equities research analysts recently issued reports on the company. Jefferies Group reiterated a “hold” rating and issued a $60.00 price objective on shares of St. Jude Medical in a research report on Monday, September 12th. Argus reiterated a “hold” rating on shares of St. Jude Medical in a research report on Sunday, August 28th. Credit Suisse Group AG reiterated a “neutral” rating and issued a $81.00 price objective on shares of St. Jude Medical in a research report on Sunday, August 28th. Barclays PLC reiterated an “equal weight” rating and issued a $83.00 price objective on shares of St. Jude Medical in a research report on Monday, August 15th. Finally, Zacks Investment Research downgraded St. Jude Medical from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Twenty-one investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $74.68.

About St. Jude Medical

St. Jude Medical, Inc is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders.

5 Day Chart for NYSE:STJ

Want to see what other hedge funds are holding STJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for St. Jude Medical Inc. (NYSE:STJ).

Receive News & Ratings for St. Jude Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for St. Jude Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.